z-logo
Premium
The efficacy and safety of topical tranexamic acid (liposomal or lotion with microneedling) versus conventional hydroquinone in the treatment of melasma
Author(s) -
Xing Xiaoxue,
Chen Li,
Xu Zhongyi,
Jin Shanglin,
Zhang Chengfeng,
Xiang Leihong
Publication year - 2020
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.13810
Subject(s) - melasma , medicine , lotion , tranexamic acid , dermatology , erythema , liposome , surgery , pharmacology , chemistry , biochemistry , blood loss
Abstract Background Robust evidence regarding the efficacy of topical tranexamic acid (TA) on melasma in Chinese population is lacking. Objective To evaluate the efficacy and safety of 1.8% liposomal TA and microneedling with 5% TA solution on melasma. Methods Sixty melasma patients were enrolled and randomized to receive 1.8% liposomal TA twice daily, microneedling with 5% TA solution weekly or 2% hydroquinone every night. Objective and subjective assessments were obtained at baseline, 4, 8, and 12 weeks. Results 27.8% of patients of liposomal TA group, 33.3% of microneedling with TA solution group, and 30.0% of hydroquinone group were recognized as “more than 50% improvement.” At the endpoint, the melanin index (MI) in all treatment groups was significantly decreased, while the improvement of MI in microneedling with TA solution group and hydroquinone group is higher than liposomal TA group. The erythema index (EI) was significantly diminished in liposomal TA group and microneedling with TA solution group. Dermatoscopy and reflectance confocal microscopy revealed decreased brown granules in all groups and reduced telangiectasia in liposomal TA group and microneedling with TA solution group. Conclusion 1.8% liposomal TA and microneedling with 5% TA solution are both effective and safe on melasma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here